System for delaying drug delivery up to seven hours
AssigneeAlza Corporation
InventorsFrank Jao, Patrick S.-L. Wong, Hoa T. Huynh, Kathy Mc Chesney, Pamela K. Wat
Life of this patent
Estimating the term…
Abstract
A dosage form is disclosed comprising means for delaying the delivery of drug from the dosage form following the administration of the dosage form to a patient in need of drug therapy.
Claims8
A dosage form for the delayed-delivery of a drug to a fluid environment of use, wherein the dosage form comprises:
- (a) a drug composition comprising a dose of 0.05 ng to 1.5 g of a calcium channel blocker drug, and a polymer comprising a molecular weight up to 1,000,000 and a rate of hydration in the presence of fluid that contacts the dosage form to change from a non-dispensable phase to a dispensable phase;
- and,
- (b) a drug-delayed delivery composition in the dosage form comprising a polymer possessing a 8,500 to 4,000,000 molecular weight that delays the delivery of the drug from the dosage form up to seven hours.
A dosage form for the delayed-delivery of a drug to a fluid environment of use, wherein the dosage form comprises:
- (a) a drug composition comprising a dose of 0.05 ng to 1.5 g of an angiotensin converting enzyme inhibitor and a polymer comprising a molecular weight up to 1,000,000 and rate of hydration in the presence of fluid that contacts the dosage form to cause the dosage form to change to a dispensable phase;
- and,
- (b) a drug-delayed delivery composition in the dosage form comprising a polymer possessing a 8,500 to 4,000,000 molecular weight that delays the delivery of the angiotensin converting enzyme inhibitor from the dosage form for up to seven hours.
A dosage form for the delayed-delivery of a drug to a patient fluid environment, wherein the dosage form comprises:
- (a) a drug composition comprising a dose of 0.05 ng to 1.5 g of a patient administrable drug and a polymer comprising a molecular weight up to 1,000,000 and a rate of hydration in the presence of fluid that contacts the dosage form to cause the dosage form to change to a dispensable phase;
- and,
- (b) a drug-delayed delivery composition in the dosage form comprising a polymer possessing a 8,500 to 4,000,000 molecular weight that delays the delivery of the drug from the dosage form for up to seven hours.
A method for the delayed-delivery of a drug to a patient in need of delayed therapy, wherein the method comprises:
- (A) admitting into the patient a dosage form comprising:
- (1) a drug composition comprising a dose of 0.05 ng to 1.5 g of a patient administrable drug and a polymer comprising a molecular weight up to 1,000,000 and a rate of hydration in the presence of fluid that contacts the dosage form to cause the dosage form to change to a dispensable phase;
- and,
- (2) a drug-delayed delivery composition in the dosage form comprising a polymer possessing a 8,500 to 4,000,000 molecular weight that delays the delivery of drug from the dosage form for up to seven hours;
- and
- (B) delivering the drug from the dosage form to obtain the indicated therapeutic intent.
A method for the delayed-delivery of a drug to a patient in need of delayed therapy, wherein the method comprises:
- (A) admitting into the patient a delayed-delivery dosage form comprising:
- (1) a drug composition comprising a dose of 0.05 ng to 1.5 g of a patient administrable drug and a pharmaceutical carrier comprising a molecular weight up to 1,000,000 for delivering the drug to the patient;
- and,
- (2) means in the dosage form comprising a molecular weight up to 4,000,000 that delays the delivery of drug from the dosage form to provide a delayed delivery of the drug up to 7 hours;
- and
- (B) delivering the drug after the delay at a delivery rate up to 40 mg/hr over an extended period of 24 hours.
Dependencies are inferred from the claim text.